BioCentury
ARTICLE | Clinical News

BBI503: Phase I data

June 2, 2014 7:00 AM UTC

Data from 20 evaluable patients with advanced solid tumors in the single-arm, open-label, dose-escalation, North American Phase I BBI503-101 trial showed that once-daily 10-450 mg doses of oral BBI503...